Risk Management & Treatment > Cancer Treatment > Biomarker Testing > Common Biomarker Tests
Biomarkers used for treatment selection
The following tumor biomarkers may be used to select treatment for the cancer types listed below. Speak with your doctor about other tests and treatments, which may be available.
Cancer | Treatment/s | |||||||
---|---|---|---|---|---|---|---|---|
Breast | Colorectal | Endometrial | Melanoma | Ovarian | Pancreatic |
|
||
BRAFV600E | X | X |
Braftovi (encorafenib) |
|||||
, | X | X | Lynparza () Rubraca () Zejula® () |
|||||
Epidermal growth factor receptor (EGFR) mutation testing |
X |
Erbitux (cetuximab) |
||||||
Estrogen/Progesterone receptor (ER/PR) expression |
X | X |
Aromatase inhibitors (AIs) |
|||||
expression | X | X | X |
Herceptin (trastuzumab) |
||||
Deficiency () |
X |
Lynparza () |
||||||
Response (HRR) pathway mutations (, , , , , CDK12, , FANCL, , RAD51B, , , RAD54) | X | Lynparza () | ||||||
KRAS mutation | X |
Erbitux (cetuximab) |
||||||
MSI-H () or dMMR/MMR-D (Mismatch Repair Deficient) | X | X | X | X | X | X | X | Keytruda (pembrolizumab) |
MSI-H () or dMMR/MMR-D (Mismatch Repair Deficient) | X | Opdivo (nivolumab) Yervoy (ipilimumab) |
||||||
dMMR/MMR-D (Mismatch Repair Deficient) | X | Jemperli (dostarlimab) | ||||||
NTRK fusion | X | X | X | X | X | X | X | Vitrakvi (larotrectinib) |
PDL1 expression | X | Tecentriq (atezolizumab) | ||||||
PIK3CA | X | Piqray (alpelisib), | ||||||
(TMB) | X | X | X | X | X | X | X | Keytruda (pembrolizumab) |